

Clinical Trials

1. Learning Objectives

After reviewing this chapter readers should be able to:

- Identify and classify different types of trial designs when reading a trial report;
- Understand the essential design issues of randomized clinical trials;
- Appreciate three possible sources of errors that could lead to erroneous trial results;
- Understand the basic statistical principles, concepts, and methods for clinical data analysis and reporting; and
- Understand some frequently used terms in clinical trials.



Office of Behavioral and
Social Sciences Research



Department of Health
and Human Services



National Institutes
of Health

2. Introduction

Randomized clinical trials are scientific investigations that examine and evaluate the safety and efficacy of new drugs, devices, tests, or lifestyle interventions using human subjects.

The primary aim of most clinical trials is to provide an unbiased evaluation of the merits of using one or more treatment options for a given disease or condition of interest.

The results that these clinical trials generate are considered to be the most robust data in the era of evidence-based medicine. Ideally, clinical trials should be performed in a way that isolates the effect of treatment on the study outcome and provides results that are free from study bias.

A common approach by which to achieve this aim is through randomization, whereby patients are assigned to a treatment group by random selection. Patients and trial personnel are deliberately kept unaware of which patient is on the new drug. This minimizes bias in the later evaluation so that the initial blind random allocation of patients to one or other treatment group is preserved throughout the trial.

Clinical trials must be designed in an ethical manner so that patients are not denied the benefit of usual treatments. Patients must give their voluntary consent that they appreciate the purpose of the trial. Several key guidelines regarding the ethics, conduct, and reporting of clinical trials have been constructed to ensure that a patient's rights and safety are not compromised by participating in clinical trials (Declaration of Helsinki, 2005; Altman et al., 2001).



Exercise 1: Importance of Clinical Trials

What do you know about clinical trials?

Choose what you think is the most important statement regarding clinical trials:

Clinical trials enable the widespread use of proven therapies.

Clinical trials are the only evidence needed for drugs to succeed.

Clinical trials are the most rigorous way of evaluating a therapy while minimizing bias.

Clinical trials are the most useful data to assess the safety of new drugs.

2. Introduction

A large proportion of clinical trials are sponsored by pharmaceutical or biotechnology companies that are developing a new disease management intervention: drug, device, or diagnostic strategy. Disease specific charities may also fund investigators to conduct studies and large central government bodies interested in health care will also sponsor scientifically valid studies. Clinical trials usually involve a program of studies from initial exploratory studies on a handful of subjects to large trials involving hundreds or thousands of subjects, requiring considerable financial investment usually into the millions of dollars over several years. Given this investment, there is often an expectation of a return from this investment. The more commercial the source of funding, the greater the expectation for financial success and the greater the pressure on those involved to produce positive results. In the last 20 years however, researchers have recognized the need to disconnect funding from the design and conduct of trials and many pharmaceutical companies now employ independent research organizations to undertake such studies.

Important clinical questions without immediate apparent commercial value but improving the delivery of care to patients or studies using older drugs in new disease areas will often be funded by health-related government agencies, or through charitable grants.

3. Classification

Clinical trials vary depending on who initiates the trial:

- Clinicians;
- Pharmaceutical or other health care companies;
- Government bodies; or
- Health providers, who may all initiate trials depending on their interest.

Typically pharmaceutical companies conduct trials involving new drugs or established drugs in disease areas where their drug may gain a new license.

Device manufacturers use trials to prove the safety and efficacy of their new device. Clinical trials initiated by clinical investigators may ask questions of when or how best to administer a specific therapy or when to withdraw a therapy and they may use established or older drugs with little commercial value in new disease areas.

Government bodies or health care providers may trial vaccines or best ways of organizing care delivery (e. g., availability of contraception methods or uptake of the measles vaccine).

Appropriate uses of clinical trials

A clinical trial is appropriate to evaluate which is the most cost effective drug choice. Clinical trials are also appropriate for evaluating whether a new device achieves a certain goal as effectively and safely as standard devices.

However, investigating the causes of Parkinson's disease, for example, is better suited by a cohort study or case-control study because cohort studies are able to observe groups to determine frequency of new incidence of disease and case-control studies observe patients with diseases to better understand disease characteristics.



Exercise 2: Reasons for Clinical Trials

Select an item from the "Groups" list and click and drag it to its corresponding "Reason" for conducting studies.

Groups who conduct studies:

Clinical Investigators
Device Manufacturers
Government Bodies or Health Care Providers
Pharmaceutical Companies

Reasons to conduct studies

Improve delivery of care	
Prove safety and efficacy	
Test drugs in disease areas where their drug may gain a new license	
Test when or how best to administer a specific therapy or withdraw a therapy	


3. Classification

Phases

For commercial purposes, trials have been classified into various phases, determined by the pharmaceutical industry based on the four phases of development of a particular drug (Phases I–IV) (Chow & Liu, 1998).



Figure 1: Basic Trial Designs



PHASES

Phase I - Test Drug in Healthy Volunteers

Test the effects of a new therapeutic agent in healthy volunteers following successful animal studies. These examine how the drug is handled in the human body (pharmacokinetics/ pharmacodynamics), particularly with respect to immediate short-term safety of higher doses.

Phase II - Test drug in Patients with the Disease

Examine dose–response curves in patients using different dosages of the therapeutic agent in usually a small group of patients with a particular disease.

Phase III - Test Drug Against Placebo

A new drug is tested in a controlled fashion in a large patient population against a placebo or standard therapy. This is a key phase, where a drug must establish superior or equivalent efficacy to standard therapy or placebo. A positive study in Phase III is often

known as a landmark study.

Phase IV - Test Drug While in the Marketplace

A postmarketing study as the drug has already been granted regulatory approval/license. These later studies are crucial for gathering additional safety information from a larger group of patients with respect to the long-term safety of the drug or for establishing a drug in a new or wider group of patients.

3. Classification

Trial design

Trials can be further classified by design. This classification is more descriptive in terms of how patients are randomized to treatment.

Parallel-Group trials are the most common design (Pocock, 1983; Friedman, 1998). Patients are randomized to the new treatment or the standard treatment and followed-up to determine the effect of each treatment in parallel groups.

Crossover trials randomize patients to different sequences of treatments, but all patients eventually get all treatments in varying order, i.e., the patient is his/her own control (Senn, 2002; Jones & Kenward, 2003; Wang et al., 2006g).


Factorial trials assign patients to more than one treatment-comparison group that are randomized in one trial at the same time; i.e., while drug A is being tested against placebo, patients are re-randomized to drug B or placebo, making four possible treatment combinations in total (Fox et al., 2006).

Cluster randomized trials are performed when larger groups (e.g., patients of a single practitioner or hospital) are randomized instead of individual patients (Mallick et al., 2006b).

Cluster trials can be any of the previously mentioned designs.



Figure 2: Basic Trial Designs



3. Classification

Number of centers

Clinical trials can also be classified as single-center or multicenter studies according to the number of sites involved. While single-site studies are mainly used for Phase I and II studies, multicenter studies can be carried out at any stage of clinical development.

Multicenter studies are necessary for two major reasons (Truesdale et al., 2006; Matthews, 2000):

- To evaluate a new medication or procedure more efficiently in terms of accruing sufficient subjects over a shorter period of time; and
- To provide a better basis for the subsequent generalization of the trial's findings, i.e., the effects of the treatment are likely to be similar in a wider setting across centers not involved in the trial.

Other classifications

Trials can also be described as superiority studies, equivalence studies, or noninferiority studies in terms of what the study was designed to prove.

- A superiority study aims to show that a new drug is more effective than the comparative treatment (placebo or current best treatment) (Pocock, 1983; Chow et al., 2003). Most clinical trials belong to this category.
- On the other hand, an equivalence trial is designed to prove that two drugs have the same clinical benefit. Hence, the trial should demonstrate that the effect of the new drug differs from the effect of the current treatment by a margin that is clinically unimportant (Bakhai et al., 2006c; Wang et al., 2006a).
- A noninferiority trial aims to show that the effect of a new treatment cannot be said to be significantly weaker than that of the current treatment.

In the latter two trials the new treatment might still turn out to be more effective than the comparative treatment, but this is not the prior assumption of the trial (Miller et al., 2006).



Exercise 3: Patient Study Design

Which study design would potentially need the most patients?

Equivalence Study

Superiority Study

Non-Inferiority Study

3. Classification

Clinical trials can also be classified by whether the trial is:

- The first to compare a specific treatment (exploratory); or
- A further trial trying to confirm a previous observation (confirmatory) (Day, 1999).

An exploratory study might also seek to identify key issues rather than to confirm or challenge existing results regarding the treatment effect. For example, it might look at the impact of a new drug in a specific subset of patients who have additional diseases to the main disease of interest, such as diabetic patients with heart disease. On occasions, a study can have both confirmatory and exploratory aspects. For instance, in a confirmatory trial evaluating a specific treatment, the data can also be used to explore further hypotheses, i.e., subgroup effects that have to be confirmed by later research.



Exercise 4: Study Design Descriptions

Click and drag the study designs to match each with the correct description.



Parallel-Group
Trial



Factorial Design



Cluster
Randomized



Cross Over

Brief Description	Study Design
While drug A is being tested against placebo, patients are re-randomized to drug B or placebo.	
Entire hospitals or physician practices are randomized to standard or new therapy rather than individuals.	
Randomize patients to different sequences of treatments, but all patients eventually get all treatments in varying order.	
Randomizing patients to either test drug or standard treatment.	

4. Endpoints

Endpoints

A clinical trial endpoint is defined as a measure that allows us to decide whether the null hypothesis of a clinical trial should be accepted or rejected (Bakhai et al., 2006a). In a clinical trial, the null hypothesis states that there is no statistically significant difference between two treatments or strategies being compared with respect to the endpoint measure chosen.

Clinical trial endpoints can be classified as primary or secondary.

Primary endpoints measure outcomes that will answer the primary (or most important) question being asked by a trial, such as whether a new treatment is better at preventing disease-related death than the standard therapy. In this case, the primary endpoint would be based on the occurrence of disease-related deaths during the duration of the trial. The size of a trial is determined by the power needed to detect a difference in this primary endpoint.

Secondary endpoints ask other relevant questions about the same study; for example, whether there is also a reduction in disease measures other than death, or whether the new treatment reduces the overall cost of treating patients. When secondary endpoints are also important the trial must be powered sufficiently to detect a difference in both endpoints, and expert statistical and design advice may be needed.

Types of Endpoints

An endpoint could take different forms:

- A quantitative (or continuous or numerical) measurement representing a specific measure or count (e.g., quality of life, blood pressure, or heart rate). These endpoints can be summarized by means and medians (Wang et al., 2006f).
- A binary clinical outcome indicating whether an event has occurred (e.g., death from any cause, the occurrence of disease signs or symptoms, the relief of symptoms). The proportions, odds ratios and risk ratios can be used to compare these endpoints (Wang et al., 2006d).

- The time to occurrence of an event of interest or survival time (e.g., the time from randomization of patient to death). Kaplan-Meier plot is often used to compare the survival experience graphically and Cox model is frequently used to estimate the treatment effect (Cox, 1984; Wang et al., 2006b).
- The use of healthcare resources (e.g. the number of hospital admissions).

Ideally, a trial should have a single endpoint based on just one outcome measure. However, as the art of trial design has evolved, most large trials have a primary (composite) endpoint consisting of multiple outcome measures. An endpoint can also be the time taken for an event to occur. For such an endpoint, the events of interest for which a time is to be recorded—such as stroke or heart attack—must be predefined. Trial endpoints can also be a quantitative measurement of a biochemical or socioeconomic parameter such as cholesterol level or quality-of-life.

4. Endpoints

Composite Endpoints

While some guidelines—such as the guidance on trial design in the International Conference on Harmonization Guideline for Good Clinical Practice —generally prefer a primary endpoint based on a single outcome that will be defined before the study begins, many recent studies include multiple outcomes as part of a composite endpoint. Exploratory clinical investigations or early-phase studies are more likely to have multiple outcomes, with some of these being developed during the study.

An example of a clinical trial with a composite endpoint of multiple outcomes is the CURE (Clopidogrel in Unstable Angina to Prevent Recurrent Events) study (Yusuf, Zhao, Mehta et al., 2001). This study looked at the effects of clopidogrel in patients with acute coronary syndromes without ST-segment elevation. In this trial, the primary endpoint was a composite of the following clinical outcomes:

- **Death from cardiovascular causes;**
- **Stroke; and**
- **Nonfatal myocardial infarction.**

When multiple outcomes can be experienced by any of the patients it is often best to present both the total number of outcomes per patient and hierarchical counts of outcomes. In the latter, only one outcome can be counted for each patient, and it is usually the most serious outcome that is recorded. The rules for the hierarchy of outcomes are usually established in advance of the trial, with a fatal outcome taking precedence over a nonfatal one. Another way of combining outcomes would be to compare the number of recurrences of identical outcomes, such as the number of seizures experienced by patients with epilepsy during a follow-up period.



Exercise 5: Not a Trial Endpoint

Which of the following is not a potential trial endpoint?

Dosage of study drug.

Time to disease relapse.

Biochemical marker of disease.

Patient's stress level.

Cost of patient's care over a given time period.

5. Design Issues

Patient Selection

The aim of a clinical trial is sometimes to investigate the efficacy of an intervention in patients with a particular disease or condition. When performing a trial, it is impossible to enroll every patient with the particular disease or condition – instead, a sample of patients is selected that represents the population of interest. Essentially, the findings from the trial should have relevance to patients in future clinical practice, i.e., the study should have external validity or generalizability.

In order to ensure generalizability:

- It is essential to have an understanding of the disease and its current treatment options.
- The selected sample must truly reflect the population it represents, and the eligibility criteria must not be so restrictive that they hamper recruitment or limit the generalizability of the findings.

However, eligibility criteria also serve the function of choosing a sample who can tolerate being in a trial and those in whom there are less co-morbidities that might dilute the effect of the intervention.

Some of the basic considerations for design in clinical trials are:

- **Patient selection**
- **Protocol**
- **Randomization**
- **Blinding**
- **Sample size determination**



Exercise 6: Lowering Blood Pressure Trial

Decide which of these patients with high blood pressure (BP) may be reasonably excluded or included from a trial looking at the benefits of lowering blood pressure using "Lopressor", a new drug?
CLICK ON EITHER "INCLUDE" OR "EXCLUDE"



Include



Exclude

Subject aged 50:



Include



Exclude

Subject with very high and very low BP:



Include



Exclude

Subject with poor kidney function:



Include



Exclude

Subject with dementia:



Include



Exclude

Subject with depression:



Include



Exclude

Subject with diabetes mellitus:

5. Design Issues

Protocol

The trial protocol is a formal document that specifies how a clinical trial is to be conducted. It describes the:

- Objective(s);
- Design;
- Methodology;
- Statistical considerations; and
- Administrative structure of the trial (Mallick et al., 2006a; ICH, 2005).

We can also regard the protocol as a scientific, administrative, and organizational project guideline that may be the basis of a contractual relationship between an investigator and a trial sponsor.

Well-designed protocols are important for conducting clinical trials safely and in a cost-effective manner.

Different trial protocols will retain very similar key components. However, adaptations may be necessary for each trial's particular circumstances.

In scientific research, the first step is to set up a hypothesis, and then to construct an appropriate study design to test that hypothesis. In clinical trials, the hypothesis is usually related to one form of therapeutic intervention that is expected to be superior or equal to another in terms of specific outcomes. Once this hypothesis is developed, the study's aims, design, methodology, statistical methods, and analyses should be formulated.

The protocol should clearly address issues related to:

- The study's conduct;
- Set up;
- Organization;

- Monitoring;
- Administrative responsibilities;
- Publication policy; and
- Timelines in appropriate sections.

Trial guidelines and regulatory requirements, such as the International Conference on Harmonization guidelines for Good Clinical Practice (ICH-GCP, 2005), the Declaration of Helsinki (Declaration of Helsinki, 2005), the EU Clinical Trials Directive (EUCTD, 2001), and the US Food and Drug Administration (FDA) Regulations Relating to Good Clinical Practice and Clinical Trials (FDA, 2005), should be followed as appropriate.

5. Design Issues

Randomization

Why should patients in a clinical trial be randomized? The randomized controlled trial (RCT) is considered the gold standard for testing the efficacy of medical treatments (Pocock, 1983).

A fundamental assumption that forms the basis of the RCT is that patients in different groups are similar for characteristics such as age, gender, social class, time of year of presentation, country of presentation, and type of hospital.

This assumption is the basis of all comparative statistical tests performed in the trial. To achieve this balance we randomly assign the patients (hence the term randomized in an RCT) to each treatment strategy so that, for example, men have an equal chance of being given treatment A or B, people aged over 60 years have an equal chance of being given treatment A or B, and so on. Simple randomization is one way of performing this balancing function, but other methods are needed when the number of patients is small.

Minimizing bias

A further requirement of randomization is that it must not be predictable by the person assigning patients to the treatment strategies; otherwise there is a chance that the groups will contain bias. To prevent this, certain methods of blinding or masking are used so that patients and staff (with the usual exception of the data and safety monitoring board) are not aware whether treatment A or B is the new treatment, or even which group patients are in (active or placebo/standard treatment), until the end of the trial. Physicians and study coordinators providing the treatments to the patients use a randomization code to find out which treatment pack has been assigned to each patient (A or B), but the code provides no information about which treatment is which (active or placebo/standard treatment). Randomization must be protected by blinding so that it remains unpredictable.

Determining randomization codes

A randomization code is a list of which treatment a subject should receive. It is usually determined by a statistician using computer-generated random numbers or a random-number table.

Some trials use methods for assigning subjects according to:

- Date of birth (odd or even years);
- Hospital record number; or
- Date of screening for the study (odd or even days).

However, these randomization methods have a level of predictability, so strictly speaking they are not acceptable methods of randomization.

Common randomization methods

The generation of a randomization code can be achieved using one of a variety of procedures. Once a code and method of allocation are decided on, their rules must be adhered to throughout the study.

Common types of randomization methods are (Wang & Bakhai, 2006a):

- Simple randomization;
- Block randomization;
- Stratified randomization; or
- Minimization or adaptive randomization.

A combination of these methods can also be used, and other special methods have also been used (Chow & Liu, 1998).

5. Design Issues

Blinding

Randomization can minimize the influence of bias in clinical trials by balancing groups for various characteristics. Bias can still occur, however, if study personnel and patients know the identity of the treatment, due to preconceptions and subjective judgment in reporting, evaluation, data processing, and statistical analysis. To minimize these biases, studies should be blinded, or masked, so that all participants are unaware of whether the subjects are assigned to the new or standard therapy during a trial.

There are four general types of blinded studies in clinical trials (Bakhai et al., 2006b):

- **Open / unblinded;**
- **Single blinded;**
- **Double blinded; and**
- **Triple blinded.**

Open / Unblinded Studies

On some occasions it might not be possible to use blinding. For example, if the new intervention is a surgical treatment and is being compared with tablets then the difference between the two is difficult to hide. Such studies might need to be unblinded as far as the patients and caregivers are concerned, and are known as open or unblinded studies. The main problem with this type is that patients may underreport adverse effects of the new treatment.

Single-Blinded Studies

In single-blinded studies, the patient should be unaware of which treatment they are taking, while the investigators are aware of whether the treatment is new, standard, or placebo. The disadvantage is that patients might under- or over-report treatment effects and side-effects, based on some influence or response from the investigators. Investigators may give advice or prescribe additional therapy to the control group if they feel that these patients are disadvantaged in comparison to the active group, and so a number of subtle biases could be

introduced either in favor of or against the new treatment depending on the investigators' opinions.

Double-Blinded Studies

In double-blinded studies, neither the patient nor the investigator knows the identity of the assigned intervention (Chow & Liu, 1998). A number of biases are thus reduced, such as investigators' preconceptions of the treatments used in the study. This reduces the ability of the investigators to monitor the safety of treatments, so a Data Safety Monitoring Committee (DSMC) must regularly review the rate of adverse events in each arm of the trial.

Operating these committees is difficult, as they must meet regularly enough to be able to detect differences promptly, avoiding needless further harm to patients, while avoiding early termination of a trial due to a chance difference.

Triple-Blinded Studies

In triple-blinded studies, in addition to the investigators and participants, all members of the sponsor's project team (e.g., the project clinician, statistician, and data manager), and even the DSMC are blinded (Chow & Liu, 1998). This lessens the chance that the DSMC will stop the trial early in favor of either treatment, and makes evaluations of the results more objective.

However, this hampers the DSMC's ability to monitor safety and efficacy endpoints, and some investigators might feel uncomfortable when participating because there is no one to oversee the results as they accrue. Triple blinding is appropriate for studies in which the risk of adverse events due to the new or standard treatment is low, and should not be used for treatments where safety is a critical issue. Due to the reduced ability of the DSMC to see trends early, recruitment might need to continue until statistical significance is reached for either clinical effects or adverse events.

5. Design Issues



Exercise 7: Blinding Methods

For each of the following example scenarios, select which blinding method you think is the best match. A blinding method may apply to more than one scenario.

Clinical Trial Scenarios

Example 1: A cardiac specialist wants to compare a new aspirin like tablet with an existing one for chronic heart disease and wants patients, doctors and the research team, all members of the sponsor's project team, not to be able to tell which patient is in which treatment groups.

Unblinded	Single Blind	Double Blind	Triple Blind
-----------	--------------	--------------	--------------

Example 2: An orthopaedic hospital team wants to compare two different types of artificial hip joints available for patients needing hip replacements.

Unblinded	Single Blind	Double Blind	Triple Blind
-----------	--------------	--------------	--------------

Example 3: A gastroenterology surgeons want to evaluate keyhole (laparoscopic) versus an open operation to remove patients' gallbladders in a trial.

Unblinded	Single Blind	Double Blind	Triple Blind
-----------	--------------	--------------	--------------

Example 4: A novel oral antithrombotic agent is to be compared with an existing oral agent for long term prophylaxis against strokes. Both patients and doctors are not aware of which treatment a patient is on.

Unblinded	Single Blind	Double Blind	Triple Blind
-----------	--------------	--------------	--------------

Example 5: A chemotherapeutic intervention for early leukemia is to be compared to a "watch and wait" approach. It is unclear how many patients will experience disease progression.

Unblinded	Single Blind	Double Blind	Triple Blind
-----------	--------------	--------------	--------------

Example 6: Two different formulations for pre-colonoscopy bowel preparation are to be compared to see which empties the colon the best. The patients are instructed not to inform the doctor performing the procedure which agent they received.

Unblinded	Single Blind	Double Blind	Triple Blind
-----------	--------------	--------------	--------------

5. Design Issues

Sample Size Determination

What is the sample size for a randomized clinical trial?

The sample size of a randomized controlled trial is the number of subjects that are to be enrolled in the study (Wang & Bakhai, 2006b; Chow et al., 2007). Choosing the right sample size is critical for a study, and is based on two key assumptions:

- **The size of the benefit we anticipate** with the new treatment compared to standard (or placebo) treatment (the 'expected treatment effect'); and
- The **amount of certainty we wish to have** with which to capture the treatment benefit (the 'power' of the study).

The larger the sample size, the better the power with which to detect a treatment effect, which means that smaller treatment effects can be detected as statistically significant. In the same way, the smaller the sample size, the less power we have with which to detect a treatment effect, meaning that the effect must be greater in order to be detected as significant. The calculation used to find the required sample size for a trial is also influenced by the trial's design, so the method by which the primary outcome is to be determined must also be clarified in advance of determining the sample size.

Why do we have to choose a sample size?

When resources are limited we must decide how best to invest those in order to maximize the benefits received. For example, should we use treatment X or treatment Y? To answer this question, we need to decide how hard we will look for the answer. Until we do, people will continue to be given or refused a treatment without evidence. We might decide that it is only worth looking at the question if we are fairly likely to detect a 10% improvement with the new treatment. To improve the chance that such a difference is detected (if it exists) we have to choose the sample size wisely, based on realistic initial assumptions. More importantly, it is unethical to carry out a study that is unlikely to capture a real difference since we will have spent precious resources on performing a study for no gain. From this, we can appreciate that

choosing an appropriate sample size for a study is dependent on good judgment, which is critical to a trial's success.

Are negative trials due to small sample sizes?

A negative clinical trial is a trial in which the observed differences between the new and standard treatments are not large enough to satisfy a specified significance level (Type I error threshold), so the results are declared to be not statistically significant (Wang et al., 2006e). With the benefit of hindsight, analyses of negative clinical trials have shown that the assumptions chosen by investigators often lead them to choose a sample size that is too small to offer a reasonable chance of avoiding a false-negative error (a Type II error).

Not all negative trials are due to insufficient power. In some cases it might be that the event rate in the control group was lower than expected or that there were confounding factors, such as changes to routine treatment methods during the duration of the study. A branch of medical statistics known as meta-analysis combines the results from many such small studies to try to estimate a true mean effect more closely. If this analysis shows that the new treatment has a favorable benefit, then this should be verified by performing a larger, definitive RCT. However, one must always take into consideration the outlay of resources required to realize the potential benefit, and even then, large RCTs might produce unexpected results.

6. Erroneous Trial Results

In a clinical trial, the observed treatment effect regarding the safety and efficacy of a new drug may represent the 'true' difference between the new drug and the comparative treatment or it may not. This is to say that if the trial were to be repeated with all the available patients in the world then the outcome would either be the same as the trial (a true result) or different (making the trial result a chance event, or an erroneous false result). Understanding the possible sources of erroneous results is critical in the appreciation of clinical trials.

Reasons for erroneous results fall into three main categories.

- **The trial may have been biased in some predictable fashion.**
- **It could have been contaminated (confounded) by an unpredictable factor.**
- **The result may simply have occurred by random chance.**



Example 1: Potential Biases

A cinnamon-based herbal oil reduced breast pain in women compared to evening primrose oil. Commercial oils were used for the study. The new cinnamon oil was provided free to all participants, while the primrose oil needed a prescription to be filled by the patient.

In this example, there are several sources of potential bias, including:

- Trial not blinded;
- New medications are appealing;
- False safety impression;
- Impressions based on age;
- Patient drop out; and
- Self-fulfilling prophecy.

The first source is not blinding the trial. This could result in bias because if the trial is not blinded, it is easy to know which oil women were on, resulting in observer bias and volunteer bias in terms of recording and reporting breast pain. New medications can be a source of bias

because they are appealing and they usually attract positive attitudes from patients and, more importantly, physicians, especially those in a trial. This is often referred to as **observer's bias**. Side effects of newer medications are not as extensively known or documented often giving a false impression of safety. This can be referred to as **information bias**. Impressions based on age can be a source of bias because younger, healthier patients are more likely to participate in the study and appreciate new products rather than the skepticism of new products that is often found in older patients. This is an example of **selection bias**. A confounding treatment effect can be caused by imbalances in subject distribution by treatment group. Non-blinded studies may not have balanced groups if people drop out if chosen for the prescription therapy arm. Another source is known as the **self fulfilling prophecy** effect. This is when physicians themselves may influence patients if they know which therapy a patient is receiving and may capture or record patient experiences during the trial with their own "pre-judgement" biases. This is also an example of observer's bias.

6. Erroneous Trial Results

Bias/systematic errors

Bias can influence a trial by the occurrence of systematic errors that are associated with the design, conduct, analysis, and reporting of the results of a clinical trial. Bias can also make the trial-derived estimate of a treatment effect deviate from its true value (Arezina & Wang, 2006; Chow & Liu, 1998; Jadad, 1998). The most common types of bias in clinical trials are those related to subject selection and outcome measurement. For example, if the investigator is aware of which treatment a patient is receiving, it could affect the way he/she collects information on the outcome during the trial or he/she might recruit patients in a way that could favor the new treatment, resulting in a selection bias.

In addition, exclusion of subjects from statistical analysis because of noncompliance or missing data could bias an estimate of the true benefit of a treatment, particularly if more patients were removed from analysis in one group than the other (Everitt & Pickles, 1999). Much of the advanced design strategies seek to reduce these systematic errors.

Confounding

Confounding represents the distortion of the true relationship between treatment and outcome by another factor, e.g., the severity of disease (Wang et al., 2006c). Confounding occurs when an extra factor is associated with both the outcome of interest and treatment group assignment. Confounding can both obscure an existing treatment difference and create an apparent difference that does not exist.

If we divided patients into treatment groups based on inherent differences (such as mean age) at the start of a trial then we would be very likely to find the benefit of the new treatment to be influenced by those pre-existing differences. For example, if we assign only smokers to get treatment A, only nonsmokers to get treatment B, and then assess which treatment protects better against cardiovascular disease, we might find that the benefit seen with treatment B is due to the lack of smoking in this group. The effect of treatment B on cardiovascular disease development would therefore be confounded by smoking.

Randomization in conjunction with a large sample size is the most effective way to restrict such confounding, by evenly distributing both known and unknown confounding factors between treatment groups. If, before the study begins, we know which factors may confound the trial

then we can use randomization techniques that force a balance of these factors (stratified randomization). In the analysis stage of a trial, we might be able to restrict confounding using special statistical techniques such as stratified analysis and regression analysis (Steele & Wang, 2006).

Random error

Even if a trial has an ideal design and is conducted to minimize bias and confounding, the observed treatment effect could still be due to random error or chance (Wang et al., 2006). The random error can result from sampling, biologic, or measurement variation in outcome variables. Since the patients in a clinical trial are only a sample of all possible available patients, the sample might yet show a chance false result compared to the overall population. This is known as a sampling error. Sampling errors can be reduced by choosing a very large group of patients. Other causes of random error are described elsewhere (Chow & Liu, 1998).

7. Statistics

Statistics play a very important role in any clinical trial from design, conduct, analysis, and reporting in terms of controlling for and minimizing biases, confounding factors, and measuring random errors. The statistician generates the randomization code, calculates the sample size, estimates the treatment effect, and makes statistical inferences, so an appreciation of statistical methods is fundamental to understanding randomized trial methods and results. Statistical analyses deal with random error by providing an estimate of how likely the measured treatment effect reflects the true effect (Wang et al., 2006). Two statistical approaches are often used for clinical data analysis: *hypothesis testing* and *statistical estimate*.

Statistics in Clinical Trials

Hypothesis Testing

Hypothesis testing or inference involves an assessment of the probability of obtaining an observed treatment difference or more extreme difference for an outcome assuming that there is no difference between two treatments (Altman, 1999; Kirkwood & Sterne, 2003; Wang et al., 2006). This probability is often called the P-value or false-positive rate. If the P-value is less than a specified critical value (e.g., 5%), the observed difference is considered to be statistically significant. The smaller the P-value, the stronger the evidence is for a true difference between treatments. On the other hand, if the P-value is greater than the specified critical value then the observed difference is regarded as not statistically significant, and is considered to be potentially due to random error or chance. The traditional statistical threshold is a P-value of 0.05 (or 5%), which means that we only accept a result when the likelihood of the conclusion being wrong is less than 1 in 20, i.e., we conclude that only one out of a hypothetical 20 trials will show a treatment difference when in truth there is none.

Statistical Estimate

Statistical estimates summarize the treatment differences for an outcome in the forms of point estimates (e.g., means or proportions) and measures of precision (e.g., confidence intervals [CIs]) (Altman, 1999; Kirkwood & Sterne, 2003; Wang et al., 2006). A 95% CI for a treatment difference means that the range presented for the treatment effect contains (when calculated in 95 out of 100 hypothetical trials assessing the same treatment effect)

the true value of treatment difference, i.e., the value we would obtain if we were to use the entire available patient population is 95% likely to be contained in the 95% CI.

Alpha (Type I) and Beta (Type II) Errors

When testing a hypothesis, two types of errors can occur. To explain these two types of errors, we will use the example of a randomized, double-blind, placebo-controlled clinical trial on a cholesterol-lowering drug 'A' in middle-aged men and women considered to be at high risk for a heart attack. The primary endpoint is the reduction in the total cholesterol level at 6 months from randomization.



Table 1: Alpha (Type I and Beta (Type II) Errors

Statistical Decision	True State of the Null Hypothesis	
	H0 True	H0 False
Reject H0	Type I error	Correct
Do not Reject H0	Correct	Type II error

The null hypothesis is that there is no difference in mean cholesterol reduction level at 6 months postdose between patients receiving drug A (μ_1) and patients receiving placebo (μ_2) ($H_0: \mu_1 = \mu_2$); the alternative hypothesis is that there is a difference ($H_a: \mu_1 \neq \mu_2$). If the null hypothesis is rejected when it is in fact true, then a Type I error (or false-positive result) occurs. For example, a Type I error is made if the trial result suggests that drug A reduced cholesterol levels when in fact there is no difference between drug A and placebo. The chosen probability of committing a Type I error is known as the significance level. As discussed above, the level of significance is denoted by α . In practice, α represents the consumer's risk, which is often chosen to be 5% (1 in 20).

On the other hand, if the null hypothesis is not rejected when it is actually false, then a Type II error (or false-negative result) occurs. For example, a Type II error is made if the trial result suggests that there is no difference between drug A and placebo in lowering the cholesterol level when in fact drug A does reduce the total cholesterol. The probability of committing a Type II

error, denoted by β , is sometimes referred to as the manufacturer's risk (Chow & Liu, 1998). The power of the test is given by $1 - \beta$, representing the probability of correctly rejecting the null hypothesis when it is in fact false. It relates to detecting a pre-specified difference.

Relationship Between Significant Testing and Confidence Interval

When comparing, for example, two treatments, the purpose of significance testing is to assess the evidence for a difference in some outcome between the two groups, while the CI provides a range of values around the estimated treatment effect within which the unknown population parameter is expected to be with a given level of confidence.

There is a close relationship between the results of significance testing and CIs. This can be illustrated using the previously described cholesterol reduction trial. If $H_0: \mu_1 = \mu_2$ is rejected at the $\alpha\%$ significance level, the corresponding $(1 - \alpha)\%$ CI for the estimated difference ($\mu_1 - \mu_2$) will not include 0. On the other hand, if $H_0: \mu_1 = \mu_2$ is not rejected at the $\alpha\%$ significance level, then $(1 - \alpha)\%$ CI will include 0.

7. Statistics

Let us assume that four randomized, double-blind, placebo-controlled trials are conducted to establish the efficacy of two weight-loss drugs (A and B) against placebo, with all subjects, whether on a drug or placebo, receiving similar instructions as to diet, exercise, behavior modification, and other lifestyle changes. The primary endpoint is the weight change (kg) at 2 months from baseline.

The difference in the mean weight change between an active drug and placebo groups can be considered as weight reduction for the active drug against placebo. Table 2 presents the results of hypothesis tests and CIs for the four hypothetical trials. The null hypothesis for each trial is that there is no difference between the active drug treatment and placebo in mean weight change.

In trial 1 of drug A, the reduction of drug A over placebo was 6 kg with only 40 subjects in each group. The P-value of 0.074 suggests that there is no evidence against the null hypothesis of no effect of drug A at the 5% significance level. The 95% CI shows that the results of the trial are consistent with a difference ranging from a large reduction of 12.6 kg in favor of drug A to a reduction of 0.6 kg in favor of placebo.



Table 2: Point Estimate and 95 % CI

Point estimate and 95% confidence interval (CI) for the difference in mean weight change from baseline between the active drug and placebo groups in four hypothetical trials of two weight reduction drugs.

Trial	Drug	No. of patients per group	Difference in mean weight change from baseline (kg) between the active drug and placebo groups	Standard deviation of difference	Standard error of difference	95% CI for difference		P-value
1	A	40	-6	15	3.4	-12.6	0.6	0.074
2	A	400	-6	15	1.1	-8.1	-3.9	0.001
3	B	40	-4	15	3.4	-10.6	2.6	0.233
4	B	800	-2	15	0.8	-3.5	-0.5	0.008

The results for trial 2 among 400 patients, again for drug A, suggest that mean weight was again reduced by 6 kg. This trial was much larger, and the P-value ($P < 0.001$) shows strong evidence against the null hypothesis of no drug effect. The 95% CI suggests that the effect of drug A is a greater reduction in mean weight over placebo of between 3.9 and 8.1 kg. Because

this trial was large, the 95% CI was narrow and the treatment effect was therefore measured more precisely.

In trial 3, for drug B, the reduction in weight was 4 kg. Since the P-value was 0.233, there was no evidence against the null hypothesis that drug B has no statistically significant benefit effect over placebo. Again this was a small trial with a wide 95% CI, ranging from a reduction of 10.6 kg to an increase of 2.6 kg for the drug B against the placebo.

The fourth trial on drug B was a large trial in which a relatively small, 2-kg reduction in mean weight was observed in the active treatment group compared with the placebo group. The P-value (0.008) suggests that there is strong evidence against the null hypothesis of no drug effect. However, the 95% CI shows that the reduction is as little as 0.5 kg and as high as 3.5 kg. Even though this is convincing statistically, any recommendation for its use should consider the small reduction achieved alongside other benefits, disadvantages, and cost of this treatment.

7. Statistics



Table 3: Key Points from Table 2 Trials

Summary of the key points from the results described in Table 2

Key points about Significance Test and CI	Examples
In a small study, a large P-value does not mean that the null hypothesis is true – 'absence of evidence is not evidence of absence.'	Trials 1 and 3
A large study has a better chance of detecting a given treatment effect than a small study, and is therefore more powerful.	Trials 2 and 4
A small study usually produces a CI for the treatment effect that is too wide to allow any useful conclusion.	Trials 1 and 3
A large study usually produces a narrow CI, and therefore a precise estimate of treatment effect.	Trials 2 and 4
The smaller the P-value, the lower the chance of falsely rejecting the null hypothesis, and the stronger the evidence for rejecting the null hypothesis.	Trials 2 and 4
Even if the P-value shows a statistically significant result, it does not mean that the treatment effect is clinically significant. The clinical importance of the estimated effects should always be assessed.	Trial 4

CI: confidence interval.

7. Statistics



Exercise 8: P-values and CI

The statements below are about P-values or confidence intervals. Indicate whether each statement is True or False.

When the P value is less than the threshold level it implies one treatment is statistically significantly different to another:



True



False

A narrow confidence interval implies a small sample size:



True



False

95% confidence interval for a difference between two population means that includes 0, implies that the p-value from a statistical test of a difference will be less than 0.05:



True



False

95% confidence intervals are about two standard errors either side of the study mean:



True



False

P being less than 5% indicates a clinical significance:



True



False

A confidence interval containing 0 suggests no statistical significant difference:



True



False

The null hypothesis should be rejected when the P-value is below the significance level:



True



False

95% confidence intervals are about two standard errors either side of the study mean:



True



False

P being less than 5% indicates a clinical significance:



True



False

A confidence interval containing 0 suggests no statistical significant difference:



True



False

The null hypothesis should be rejected when the P-value is below the significance level:



True



False

95% confidence interval will include 95% of the observations in the sample:



True



False

A P-value can give insights into whether the trial was adequately powered to answer the original question:



True



False

A P-value can say how effective or different a new treatment is compared with the standard treatment:



True



False

8. Summary

There has been an increasing number of randomized clinical trials conducted and published which provide the cornerstone of evidence-based medicine. More and more people from a broad range of professional backgrounds need to understand the essentials of clinical trials regarding their design, statistical analysis, and reporting. In this chapter, we provided an introduction to the area of clinical trials covering some of the key issues to be considered in their design, analysis and interpretation. Firstly, we described the general aims of clinical trials and their classifications according to different criteria. Secondly, we introduced some essential design issues in clinical trials, including endpoints, patient selection, protocol development, randomization, blinding, and sample size determination. Thirdly, we discussed three possible sources of errors that may influence trial results: bias/systematic errors, confounding, and random error. Next, we described some basic statistical concepts and methods frequently used in the analysis of randomized trials. These included descriptive statistics, statistical inferences, techniques for the comparison of means or proportions from two samples, and survival analysis. To facilitate understanding of the concepts, we also provided frequently used statistical terms and their meanings. In conclusion, readers should have sufficient knowledge, via the concepts discussed in this chapter, to appreciate the essential elements of most clinical trial reports.

9. Glossary of Terms

GLOSSARY

Bias

Systematic errors associated with the inadequacies in the design, conduct, or analysis of a trial on the part of any of the participants of that trial (patients, medical personnel, trial coordinators or researchers), or in publication of its the results, that make the estimate of a treatment effect deviate from its true value. Systematic errors are difficult to detect and cannot be analyzed statistically but can be reduced by using randomization, treatment concealment, blinding, and standardized study procedures.

Confidence Intervals

A range of values within which the "true" population parameter (e.g. mean, proportion, treatment effect) is likely to lie. Usually, 95% confidence limits are quoted, implying that there is 95% confidence in the statement that the "true" population parameter will lie somewhere between the lower and upper limits.

Confounding

A situation in which a variable (or factor) is related to both the study variable and the outcome so that the effect of the study variable on the outcome is distorted. For example, if a study found that coffee consumption (study variable) is associated with the risk of lung cancer (outcome), the confounding factor here would be cigarette smoking, since coffee is often drunk while smoking a cigarette which is the true risk factor for lung cancer. Thus we can say that the apparent association of coffee drinking with lung cancer is due to confounding by cigarette smoking (confounding factor). In clinical trials, confounding occurs when a baseline characteristic (or variable) of patients is associated with the outcome, but unevenly distributed between treatment groups. As a result, the observed treatment difference from the unadjusted (univariate) analysis can be explained by the imbalanced distribution of this variable.

Covariates

This term is generally used as an alternative to explanatory variables in the regression

analysis. However, more specifically refer to variables that are not of primary interest in an investigation. Covariates are often measured at baseline in clinical trials because it is believed that they are likely to affect the outcome variable, and consequently need to be included to estimate the adjusted treatment effect.

Descriptive / Inferential Statistics

Descriptive statistics are used to summarize and describe data collected in a study. To summarize a quantitative (continuous) variable, measures of central location (i.e. mean, median, and mode) and spread (e.g. range and standard deviation) are often used, whereas frequency distributions and percentages (proportions) are usually used to summarize a qualitative variable. Inferential statistics are used to make inferences or judgments about a larger population based on the data collected from a small sample drawn from the population. A key component of inferential statistics is hypothesis testing. Examples of inferential statistical methods are t-test and regression analysis.

Endpoint

Clearly defined outcome associated with an individual subject in a clinical research. Outcomes may be based on safety, efficacy, or other study objectives (e.g. pharmacokinetic parameters). An endpoint can be quantitative (e.g. systolic blood pressure, cell count), qualitative (e.g. death, severity of disease), or time-to-event (e.g. time to first hospitalization from randomization).

Hazard Ratio

In survival analysis, hazard (rate) represents instantaneous event rate (incidence rate) at certain time for an individual who has not experienced an event at that time. Hazard ratio compares two hazards of having an event between two groups. If the hazard ratio is 2.0, then the hazard of having an event in one group is twice the hazard in the other group. The computation of the hazard ratio assumes that the ratio is consistent over time (proportional hazards assumption).

Hypothesis Testing or Significance Testing

Statistical procedure for assessing whether an observed treatment difference was due to random error (chance) by calculating a P-value using the observed sample statistics such as mean, standard deviation, etc. The P-value is the probability that the observed data or

more extreme data would have occurred if the null hypothesis (i.e. no true difference) were true. If the calculated P-value is a small value (like <0.05), the null hypothesis is then rejected, and we state that there is a statistically significant difference.

Intention-to-Treat Analysis

A method of data analysis on the basis of the intention to treat a subject (i.e. the treatment regimen a patient was assigned at randomization) rather than the actual treatment regimen he received. It has the consequence that subjects allocated to a treatment group should be followed up, assessed, and analyzed as members of that group regardless of their compliance to that therapy or the protocol, irrespective of whether they later crossed over to the other treatment group or not or whether they discontinued treatment.

Kaplan-Meier Estimate and Survival Curve

A survival curve shows an estimate of the fraction of patients who survive over the follow up period of the study without an event of interest (e.g. death). The Kaplan-Meier estimate is a simple way of computing the survival curve taking into account patients who were lost to follow up or any other reasons for incomplete results (known as censored observations). It usually provides a staircase graph of the fraction of patients remaining free of event over time.

Meta-Analysis

The systematic review and evaluation of the evidence from two or more independent studies asking the same clinical question to yield an overall answer to the question.

Number needed to treat (NNT)

This term is often used to describe how many patients would need to be given a treatment to prevent one event. It is determined from the absolute difference between one treatment and another. In a randomized study the group receiving treatment A had a death rate of 12.5%, and the group receiving treatment B had a death rate of 15.0%. Both groups are matched for size and length of follow-up. Comparing the two treatments there was an absolute risk reduction of $15\% - 12.5\% = 2.5\%$ for treatment A. From this we can derive that the NNT ($= 1/0.025$) is 40. This means 40 patients need to be given treatment A rather than B to prevent 1 additional death.

Odds Ratio (OR) and Risk Ratio (RR)

These terms compare the probability of having an event between two groups exposed to a risk factor or treatment. The risk ratio (RR) is the ratio of the probability of occurrence of an event between two groups. The odds ratio (OR) is the ratio of the ratio of patients with and without an event in each group. If the number of deaths in the treatment and control arms (both of sample size 100) of a randomized study are 50 and 25 respectively, the $RR = (50/100) / (25/100) = 2$. The treatment group has a 2- fold relative risk of dying compared with the control group. The $OR = (50/50) / (25/75) = 3$ indicates that the odds of death in the treatment arm is 3-fold of the control arm.

Per-Protocol Analysis

A method of analysis in which only the subset of subjects who complied sufficiently with the protocol are included. Protocol compliance includes exposure to treatment, availability of measurements, correct eligibility, and absence of any other major protocol violations. This approach contrasts with the more conservative and widely accepted "intention-to-treat" analysis.

Power

The probability of rejecting the null hypothesis (e.g. no treatment difference) when it is false. It is the basis of procedures for calculating the sample size required to detect an expected treatment effect of a particular magnitude.

Random Error

An unpredictable deviation of an observed value from a true value resulting from sampling variability. It is a reflection of the fact that the sample is smaller than the population; for larger samples, the random error is smaller, as opposed to systematic errors (bias) that keep adding up because they all go in the same direction.

Regression Analyses

Methods of explaining or predicting outcome variables using information from explanatory variables. Regression analyses are often used in clinical trials to estimate the adjusted treatment effect taking into account of differences in baseline characteristics, and in epidemiological studies to identify prognostic factors while controlling for potential confounders. Commonly used regression models include linear, logistic, and Cox regression methods.

Treatment Effect

An effect attributed to a treatment in a clinical trial, often measured as the difference in a summary measure of an outcome variable between treatment groups. Commonly expressed as difference in means for a continuous outcome, a risk difference, risk ratio, or odds ratio for a binary outcome, and hazard ratio for a time-to-event outcome.

10. References

- Altman DG. (1999). Practical Statistics for medical research. London: Chapman and Hall.
- Altman DG, Schulz KF, Moher D, et al. (2001). The revised CONSORT statement for reporting randomized trials: Explanation and elaboration. *Ann Intern Med*;134: 663–94.
- Arezina R, Wang D. (2006). Source and control of bias. In: D Wang & A Bakhai, (Ed.s). *Clinical Trials: A practical guide to design, analysis and reporting*. London: Remedica. 55-64.
- Bakhai A, Chhabra A, Wang D. (2006a). Endpoints. In: D Wang & A Bakhai, (Ed.s). *Clinical Trials: A practical guide to design, analysis and reporting*. London: Remedica. 37-45.
- Bakhai A, Patel S, Wang D. (2006b). Blinding. In: D Wang & A Bakhai, (Ed.s). *Clinical Trials: A practical guide to design, analysis and reporting*. London: Remedica. 75-80.
- Bakhai A, Sudhir R, Wang D. (2006c). Equivalence Trials. In: D Wang & A Bakhai, (Ed.s). *Clinical Trials: A practical guide to design, analysis and reporting*. London: Remedica. 113-118.
- Chow SC, Liu JP. (1998). Design and analysis of clinical trials: Concept and methodologies. Chichester: John Wiley & Sons.
- Chow SC, Shao J, Wang H. (2003). Sample size calculation in clinical research. New York: Marcel.
- Chow SC, Shao J, and Wang, H (2007). Sample size calculations in clinical research. 2nd edition. Chapman Hall/CRC Press, Taylor & Francis: New York.
- Cox DR, Oakes D. (1984). Analysis of survival data. London: Chapman and Hall.
- Day S. (1999). Dictionary of clinical trials. Chichester: John Wiley & Sons.
- Declaration of Helsinki. Ethical Principles for Medical Research Involving Human Subjects. Available from: <http://www.wma.net/en/30publications/10policies/b3/index.html>. Accessed May 6, 2005.
- Directive 2001/20/EC of the European Parliament and of the Council of 4 April 2001 on the approximation of the laws, regulations and administrative provisions of the Member States

relating to the implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use. Official Journal of the European Union 2001;121:34.

Everitt BS, Pickles A. (1999). Statistical aspects of the design and analysis of clinical trials. London: Imperial College Press.

FDA, Regulations Relating to Good Clinical Practice and Clinical Trials. Available from: <http://www.fda.gov/oc/gcp/regulations.html>. Accessed May 6, 2005.

FDA, Section 5.8 of the International Conference on Harmonization: Guidance on Statistical Principles for Clinical Trials. Available from: <http://www.fda.gov/ScienceResearch/SpecialTopics/RunningClinicalTrials/ucm114928.htm>. Accessed March 31, 2005.

Fox Z, et al. (2006). Factorial design. In: D Wang & A Bakhai, (Ed.s). Clinical Trials: A practical guide to design, analysis and reporting. London: Remedica. 101-112.

Friedman LM, Furberg CD, Demets D. (1998). Fundamentals of clinical trials, 3rd edition. New York: Springer Verlag.

International Conference on Harmonisation. E6: Good Clinical Practice: Consolidated Guidelines. Available from: <http://www.ich.org/cache/compo/276-254-1.html>. Accessed May 6, 2005.

Jadad AR. (1998). Randomized controlled trials: A user's guide. London: BMJ Books.

Jones B, Kenward MG. (2003). Design and analysis of cross-over trials, 2nd edition. London: Chapman and Hall/CRC.

Kirkwood B, Sterne J. (2003). Essential medical statistics, 2nd edition. Oxford: Blackwell Publishing.

Mallick U, et al. (2006a). Protocol development. In: D Wang & A Bakhai, (Ed.s). Clinical Trials: A practical guide to design, analysis and reporting. London: Remedica. 23-36.

Mallick U, et al. (2006b). Cluster randomized trials. In: D Wang & A Bakhai, (Ed.s). Clinical Trials: A practical guide to design, analysis and reporting. London: Remedica. 141-151.

Matthews JNS. (2000). Introduction to randomized controlled clinical trials. London: Arnold.

Miller S, Neate C, Wang D. (2006). Noninferiority trials. In: D Wang & A Bakhai, (Ed.s). Clinical Trials: A practical guide to design, analysis and reporting. London: Remedica. 131-140.

Pocock SJ. (1983). Clinical trials: A practical approach. Chichester: John Wiley & Sons.

Senn S. (2002). Cross-over trials in clinical research, 2nd edition. Chichester: John Wiley & Sons.

Steele, F. Wang, D. (2006). Regression Analyses. In: D Wang & A Bakhai A, (Ed.s). Clinical trials: A practical guide to design, analysis and reporting. London: Remedica. 273-286.

Truesdale A, Bakhai A, Wang D. (2006). Multicenter trials. In: D Wang & A Bakhai, (Ed.s). Clinical trials: A practical guide to design, analysis and reporting. London: Remedica. 153-163.

Wang D & Bakhai A, editors. (2006). Clinical Trials: A Practical Guide to Design, Analysis and Reporting. London: Remedica.

Wang D, Bakhai A. (2006a). Randomization. In: D Wang & A Bakhai, (Ed.s). Clinical trials: A practical guide to design, analysis and reporting. London: Remedica. 65-73.

Wang D, Bakhai A. (2006b). Sample Size and Power. In: D Wang & A Bakhai, (Ed.s). Clinical trials: A practical guide to design, analysis and reporting. London: Remedica. 81-87.

Wang D, Arezina R, Bakhai A. (2006a). Bioequivalence Trials. In: D Wang & A Bakhai, (Ed.s). Clinical trials: A practical guide to design, analysis and reporting. London: Remedica. 119-130.

Wang D, Clayton T, Bakhai A. (2006b). Analysis of Survival Data. In: D Wang & A Bakhai, (Ed.s). Clinical trials: A practical guide to design, analysis and reporting. London: Remedica. 235-254.

Wang D, Clayton T, Bakhai A. (2006c). Confounding. In: D Wang & A Bakhai, (Ed.s). Clinical trials: A practical guide to design, analysis and reporting. London: Remedica. 295-304.

Wang D, Clayton T, Clemens F. (2006d). Comparison of Proportions. In: D Wang & A Bakhai, (Ed.s). Clinical trials: A practical guide to design, analysis and reporting. London: Remedica. 217-234.

Wang D, Clayton T, Yan H. (2006e). Significance Tests and Confidence Intervals. In: D Wang & A Bakhai, (Ed.s). Clinical trials: A practical guide to design, analysis and reporting. London: Remedica. 185-196.

Wang D, Clemens F, Clayton T. (2006f). Comparison of Means. In: D Wang & A Bakhai, (Ed.s). Clinical trials: A practical guide to design, analysis and reporting. London: Remedica. 197-216.

Wang D, Lorch U, Bakhai A. (2006g). Crossover Trials. In: D Wang & A Bakhai, (Ed.s). Clinical trials: A practical guide to design, analysis and reporting. London: Remedica. 91-99.

Yusuf S, Zhao F, Mehta SR et al. (2001). Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med;345: 494–502.

11. Author Biographies

Duolao Wang, MSc, PhD is a senior lecturer in medical statistics at Medical Statistics Unit, London School of Hygiene and Tropical Medicine, University of London, UK. Dr. Wang is an applied statistician with research interests centering on application of state-of-the-art mathematical and statistical models and techniques to discover substantive facts and/or assess theories about medical, biological, demographic, environmental and social determinants of disease and health. His research interests include: (1) health intervention studies and clinical trials; (2) reproductive health, demography and epidemiology; (3) statistical methodology and computing.

He has published more than 80 articles on medical and epidemiological research as well as statistical methodology in peer-reviewed journals including NEJM, JAMA, Circulation, American Heart Journal, European Heart Journal, Gut, Human Reproduction, Demography, Population Studies, Journal of Applied Statistics, and Statistics in Medicine, etc. He is a co-author of the book "Clinical Trials: A Practical Guide to Design, Analysis and Reporting", which has sold over 15,000 copies worldwide since its publication in January 2006.

Ameet Bakhai, MD, MRCP is a consultant cardiologist and physician at Barnet General & Royal Free Hospitals, London, UK. Dr Bakhai has particular experience in design, conduct, and analysis of clinical trials, registry studies, and health technology assessments at a national and international level. He has worked in clinical trials for 7 years, directing coronary intervention trials and leading collaborative Health Technology Assessments commissioned for groups such as the UK National Institute for Clinical Excellence. He has over 50 publications and gained statistical, trial, and economic evaluation expertise at the Harvard Clinical Research Institute. He is also a director of the Asha Medical Outcomes Research and Economic (AMORE) studies group.

Dr Bakhai has also been involved in the promotion and evaluation of guideline-based clinical practice. His research interests include health economics, interventional trials, acute coronary syndromes, and statistics. His specific focus is on enabling the use of guidelines with health economic data to overcome common barriers.